MSH3 Mismatch Repair Protein Regulates Sensitivity to Cytotoxic Drugs and a Histone Deacetylase Inhibitor in Human Colon Carcinoma Cells

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Park, Jae Myung ^a   Huang, Shengbing ^a   Tougeron, David ^a,b   Sinicrope, Frank A ^a  

^a MAYO CLINIC CANCER CENTER   (United States)

^b Department of Gastroenterology ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABEXINOSTAT; CASPASE 3; CASPASE 7; CHECKPOINT KINASE 2; FIRTECAN; FLUOROURACIL; HISTONE H2AX; OXALIPLATIN; PROTEIN MLH1; PROTEIN MSH3; RAD51 PROTEIN; SHORT HAIRPIN RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; CHROMOSOME 3; CHROMOSOME 5; CLONOGENESIS; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVITY; GENE SILENCING; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; BENZOFURANS; CAMPTOTHECIN; CELL DEATH; CELL NUCLEUS; CELL SURVIVAL; COLONIC NEOPLASMS; DNA DAMAGE; DNA MISMATCH REPAIR; DNA-BINDING PROTEINS; DRUG SCREENING ASSAYS, ANTITUMOR; FLUORESCENT ANTIBODY TECHNIQUE; FLUOROURACIL; GENE KNOCKDOWN TECHNIQUES; HCT116 CELLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; NUCLEAR PROTEINS; ORGANOPLATINUM COMPOUNDS; RAD51 RECOMBINASE;

EID: 84878420550     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065369     Document Type: Article

References (55)

1. Boland CR, Goel A (2010) Microsatellite instability in colorectal cancer. Gastroenterology 138:2073-2087 e2073.
2. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M, (1993) Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363: 558-561.
3. Acharya S, Wilson T, Gradia S, Kane MF, Guerrette S, et al. (1996) hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. Proc Natl Acad Sci U S A 93: 13629-13634.
4. Fishel R, (1998) Mismatch repair, molecular switches, and signal transduction. Genes Dev 12: 2096-2101.
5. Poynter JN, Siegmund KD, Weisenberger DJ, Long TI, Thibodeau SN, et al. (2008) Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev 17: 3208-3215.
6. Popat S, Hubner R, Houlston RS, (2005) Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23: 609-618.
7. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, et al. (2010) Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28: 3219-3226.
8. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, et al. (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349: 247-257.
9. Haugen AC, Goel A, Yamada K, Marra G, Nguyen TP, et al. (2008) Genetic instability caused by loss of MutS homologue 3 in human colorectal cancer. Cancer Res 68: 8465-8472.
10. Woerner SM, Yuan YP, Benner A, Korff S, von Knebel Doeberitz M, et al. (2010) SelTarbase, a database of human mononucleotide-microsatellite mutations and their potential impact to tumorigenesis and immunology. Nucleic Acids Res 38: D682-689.
11. Plaschke J, Kruger S, Jeske B, Theissig F, Kreuz FR, et al. (2004) Loss of MSH3 protein expression is frequent in MLH1-deficient colorectal cancer and is associated with disease progression. Cancer Res 64: 864-870.
12. Yamamoto H, Sawai H, Perucho M, (1997) Frameshift somatic mutations in gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res 57: 4420-4426.
13. Malkhosyan S, Rampino N, Yamamoto H, Perucho M, (1996) Frameshift mutator mutations. Nature 382: 499-500.
14. Muzny DM, Bainbridge MN, Chang K, Dinh HH, Drummond JA, et al. (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337.
15. Ohmiya N, Matsumoto S, Yamamoto H, Baranovskaya S, Malkhosyan SR, et al. (2001) Germline and somatic mutations in hMSH6 and hMSH3 in gastrointestinal cancers of the microsatellite mutator phenotype. Gene 272: 301-313.
16. Watanabe A, Ikejima M, Suzuki N, Shimada T, (1996) Genomic organization and expression of the human MSH3 gene. Genomics 31: 311-318.
17. Edelmann W, Umar A, Yang K, Heyer J, Kucherlapati M, et al. (2000) The DNA mismatch repair genes Msh3 and Msh6 cooperate in intestinal tumor suppression. Cancer Res 60: 803-807.
18. Reynolds MF, Peterson-Roth EC, Bespalov IA, Johnston T, Gurel VM, et al. (2009) Rapid DNA double-strand breaks resulting from processing of Cr-DNA cross-links by both MutS dimers. Cancer Res 69: 1071-1079.
19. Takahashi M, Koi M, Balaguer F, Boland CR, Goel A, (2011) MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor. J Biol Chem 286: 12157-12165.
20. Chaney SG, Campbell SL, Bassett E, Wu Y, (2005) Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 53: 3-11.
21. Zhang N, Lu X, Zhang X, Peterson CA, Legerski RJ, (2002) hMutSbeta is required for the recognition and uncoupling of psoralen interstrand cross-links in vitro. Mol Cell Biol 22: 2388-2397.
22. Hong Z, Jiang J, Hashiguchi K, Hoshi M, Lan L, et al. (2008) Recruitment of mismatch repair proteins to the site of DNA damage in human cells. J Cell Sci 121: 3146-3154.
23. Kotian S, Liyanarachchi S, Zelent A, Parvin JD, (2011) Histone deacetylases 9 and 10 are required for homologous recombination. J Biol Chem 286: 7722-7726.
24. Uhl M, Csernok A, Aydin S, Kreienberg R, Wiesmuller L, et al. (2010) Role of SIRT1 in homologous recombination. DNA Repair (Amst) 9: 383-393.
25. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, et al. (2008) GammaH2AX and cancer. Nat Rev Cancer 8: 957-967.
26. Stevens C, Smith L, La Thangue NB, (2003) Chk2 activates E2F-1 in response to DNA damage. Nat Cell Biol 5: 401-409.
27. Li J, Stern DF, (2005) DNA damage regulates Chk2 association with chromatin. J Biol Chem 280: 37948-37956.
28. Kinner A, Wu W, Staudt C, Iliakis G, (2008) Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res 36: 5678-5694.
29. Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, et al. (1999) Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117: 123-131.
30. Adimoolam S, Sirisawad M, Chen J, Thiemann P, Ford JM, et al. (2007) HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci U S A 104: 19482-19487.
31. Iwaizumi M, Tseng-Rogenski S, Carethers JM, (2011) DNA mismatch repair proficiency executing 5-fluorouracil cytotoxicity in colorectal cancer cells. Cancer Biol Ther 12: 756-764.
32. Tajima A, Iwaizumi M, Tseng-Rogenski S, Cabrera BL, Carethers JM, (2011) Both hMutSalpha and hMutSss DNA mismatch repair complexes participate in 5-fluorouracil cytotoxicity. PLoS One 6: e28117.
33. Liu A, Yoshioka K, Salerno V, Hsieh P, (2008) The mismatch repair-mediated cell cycle checkpoint response to fluorodeoxyuridine. J Cell Biochem 105: 245-254.
34. Meyers M, Wagner MW, Hwang HS, Kinsella TJ, Boothman DA, (2001) Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 61: 5193-5201.
35. Meyers M, Wagner MW, Mazurek A, Schmutte C, Fishel R, et al. (2005) DNA mismatch repair-dependent response to fluoropyrimidine-generated damage. J Biol Chem 280: 5516-5526.
36. Laghi L, Bianchi P, Delconte G, Celesti G, Di Caro G, et al. (2012) MSH3 protein expression and nodal status in MLH1-deficient colorectal cancers. Clinical cancer research: an official journal of the American Association for Cancer Research 18: 3142-3153.
37. Lee SY, Chung H, Devaraj B, Iwaizumi M, Han HS, et al. (2010) Microsatellite alterations at selected tetranucleotide repeats are associated with morphologies of colorectal neoplasias. Gastroenterology 139: 1519-1525.
38. Arnold CN, Goel A, Boland CR, (2003) Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 106: 66-73.
39. Pocard M, Bras-Goncalves R, Hamelin R, Northover J, Poupon MF, (2000) Response to 5-fluorouracil of orthotopically xenografted human colon cancers with a microsatellite instability: influence of P53 status. Anticancer Res 20: 85-90.
40. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, et al. (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56: 4881-4886.
41. Vilar E, Scaltriti M, Balmana J, Saura C, Guzman M, et al. (2008) Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br J Cancer 99: 1607-1612.
42. Magrini R, Bhonde MR, Hanski ML, Notter M, Scherubl H, et al. (2002) Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int J Cancer 101: 23-31.
43. Bras-Goncalves RA, Rosty C, Laurent-Puig P, Soulie P, Dutrillaux B, et al. (2000) Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status. Br J Cancer 82: 913-923.
44. Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, et al. (2009) Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 27: 1814-1821.
45. Tejpar S, Bosman F, Delorenzi M, Fiocca R, Yan P, et al. (2009) Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial). J Clin Oncol 27: (suppl; abstr 4001).
46. Miquel C, Jacob S, Grandjouan S, Aime A, Viguier J, et al. (2007) Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability. Oncogene 26: 5919-5926.
47. Giannini G, Rinaldi C, Ristori E, Ambrosini MI, Cerignoli F, et al. (2004) Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability. Oncogene 23: 2640-2647.
48. Sugawara N, Paques F, Colaiacovo M, Haber JE, (1997) Role of Saccharomyces cerevisiae Msh2 and Msh3 repair proteins in double-strand break-induced recombination. Proc Natl Acad Sci U S A 94: 9214-9219.
49. Pellegrini L, Yu DS, Lo T, Anand S, Lee M, et al. (2002) Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature 420: 287-293.
50. Nojima K, Hochegger H, Saberi A, Fukushima T, Kikuchi K, et al. (2005) Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells. Cancer Res 65: 11704-11711.
51. van Waardenburg RC, de Jong LA, van Delft F, van Eijndhoven MA, Bohlander M, et al. (2004) Homologous recombination is a highly conserved determinant of the synergistic cytotoxicity between cisplatin and DNA topoisomerase I poisons. Mol Cancer Ther 3: 393-402.
52. Schreiber V, Dantzer F, Ame JC, de Murcia G, (2006) Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7: 517-528.
53. Campregher C, Schmid G, Ferk F, Knasmuller S, Khare V, et al. (2012) MSH3-deficiency initiates EMAST without oncogenic transformation of human colon epithelial cells. PloS one 7: e50541.
54. Koi M, Umar A, Chauhan DP, Cherian SP, Carethers JM, et al. (1994) Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 54: 4308-4312.
55. Huang S, Okumura K, Sinicrope FA, (2009) BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. Clin Cancer Res 15: 150-159.